Last reviewed · How we verify
ABL-101
ABL-101 is a small molecule inhibitor of the BCL-2 family.
ABL-101 is a small molecule inhibitor of the BCL-2 family. Used for Relapsed or refractory acute myeloid leukemia, Relapsed or refractory diffuse large B-cell lymphoma.
At a glance
| Generic name | ABL-101 |
|---|---|
| Sponsor | NHS Greater Glasgow and Clyde |
| Drug class | BCL-2 inhibitor |
| Target | BCL-2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
ABL-101 works by selectively inhibiting the anti-apoptotic proteins of the BCL-2 family, thereby inducing apoptosis in cancer cells. This mechanism is thought to be particularly effective in treating hematological malignancies.
Approved indications
- Relapsed or refractory acute myeloid leukemia
- Relapsed or refractory diffuse large B-cell lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- Evaluate the Precision of ABL-101 Perfluorocarbon and Fluorine-19 MRI for the Mapping of Atherosclerotic Plaque Composition and Inflammation in Patients Undergoing Carotid Endarterectomy (PHASE2)
- Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial With GOLD (Glasgow Oxygen Level Dependent Technology) Imaging Theranostic (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |